Health Economics›Non-small cell lung cancer›Advanced or metastatic disease EGFR inhibitor-exposed

Advanced or metastatic disease EGFR inhibitor-exposed

Non-small cell lung cancer · 9 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy · 7 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Carboplatin, Pemetrexed, Amivantamab Variant #01	EGFR	R 753 501	21d	8.9 mo	—	5	R 1 151 463 PFS proxy	2
Carboplatin, Lazertinib, Pemetrexed, Amivantamab Variant #01 Partial	EGFR	R 611 397	21d	8.3 mo	—	6	R 1 107 846 PFS proxy	1
Lazertinib and Amivantamab Variant #01 Partial	EGFR	R 426 311	28d	23.7 mo	—	2	R 511 573 PFS proxy	2
ABCP Variant #05	EGFR	R 63 886	21d	8.5 mo	—	2	R 127 771 PFS proxy	1
Afatinib and Bevacizumab Variant #01	EGFR	R 49 520	21d	—	—	~2	~R 99 041 indirect	—
Afatinib and Cetuximab Variant #01	EGFR	R 30 560	14d	—	—	~2	~R 61 120 indirect	—
Afatinib monotherapy Variant #01	EGFR	R 26 046	28d	11.0 mo	—	2	R 52 091 PFS proxy	4
Carboplatin and Pemetrexed Variant #01	EGFR	R 14 563	21d	5.6 mo	22.5 mo	10	R 140 276 PFS proxy	18
Cisplatin and Pemetrexed Variant #01	EGFR	R 13 666	21d	5.5 mo	22.5 mo	7	R 94 340 PFS proxy	20

9 of 9 regimens shown